Allergy Therapeutics plc (AIM:AGY) Interim Results for the six months ended 31st December 2017. CEO Manuel Llobet and Financial Director Nick Wykeman discuss the company's operations, financials, clinical trials and strategy. Allergy manufacture vaccines for a range of Allergies from dust mites to wasp stings, with products selling throughout Europe. They also have a number of solutions in various stages of clinical trial, including a peanut allergy vaccine, a grass vaccine and a Birch vaccine